Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLPG3970 in Moderately to Severely Active Ulcerative Colitis
NCT04577794Phase 2Completed
- Sponsor
- Galapagos NV
- Start
- Oct 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of GLPG3970 in ulcerative colitis (UC), sponsored by Galapagos NV. Started Oct 2020; status: completed.
02
Drugs
GLPG3970
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04577794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04577794.